Pancy SME for the application for a MSCA Postdoctoral Fellowship

The main commitment of the SME will be to care for and effect the implementation of the two Research (Sub)Projects dedicated to newly emerging or worsening diseases, increasingly appreciated as deriving from the intertwining of communicable and non-communicable illnesses. Especially, the project rests upon the documentation of the greatly after-COVID-19 increased prevalence of hypertension and cardiovascular & metabolic outcomes, previous main research interest, jointly with IGF-1 pathophysiology, of the Pancy SME promoter, and part of the inner leaders’ circle. The neurological and the neurovascular outcomes, too, registered during Sars-CoV, Sars-CoV-2, and post-COVID-19 era, appeared to be profoundly modified by newly emergent Sars-CoV-2-coinfected Taeniasis-cysticercosis disease. New data ease the suspicion that an increased rate of cardiometabolic illnesses was induced by the crucially interplaying role of the Taenia-cysticercosis on Sars-CoV-2 disease, demanding a specific and separate diagnostic & therapeutic effort, and for deepened investigations on mitochondrial-, B vitamin- and ACE2-modifying cysticercosis effects, deeply involved in the pathogenesis of many heart-cardiovascular and brain-neurological-neurovascular diseases.

The strategic vision of the microSME will be that of reconnecting worlds and peoples, across the management of this zoonotic in dynamic, but human in nature, disease, since human beings are the definitive host of Cysticercosis. The strategic mission will be that of uncompromisingly pursuing the care and the cure of the single and of the Sars-CoV-2-intertwined cysticercosis disease, ambitiously willing to establish milestones for the definition of its natural history, complications, care, and hopefully innovative cures for all the unfolded pathogenetic potential of the disease, and hopefully vaccines.   This old, better defined “ancient”, and together oddly untackled disease, in time increasingly widespread worldwide, can no longer be considered neglected. Being re-emerged as an effect of the concurrent SARS-CoV/Sars-CoV-2 pandemics, more relevant per prevalence, and of the HIV epidemic, more relevant per severity, cysticercosis currently counts, according to some, up to 11 million people affected in Europe, 12 million affected people in the United States by March 2024, and 50 million affected with larvae worldwide.

A unique experience of population “snapshots”, big picture views, and of the direct and innermost understanding of infectious and preventive medicine issues at the population level is also forecasted as possibly achieved from this SME, by widening the arena of the involved countries, at the moment limited to three (Italy, France, United States). A fruitful interchange is also expected to establish between infectious disease specialists' and cardiologists' perspectives, setting an in-depth evaluation of the real bond already instituted, and even more widening among communicable and non-communicable diseases. To this, the pathophysiological arms of both to be realised at A and B subsegments by Professor Spielman and LeGoff, respectively, could become enlightening.

Lastly, the importance of B1-B12 vitamin replenishment in the short-, medium-, and long-term, for care of either cardiovascular-respiratory or neurological clinical manifestations, will also be addressed.